|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
To investigate this hypothesis, db/db diabetic mice were used to establish a DKD model and the PPARγ agonist rosiglitazone was employed to induce PGC‑1α expression in vivo.
|
29344670 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Impact of Peroxisome Proliferator-Activated Receptor Gamma and Its Interaction with Abdominal Obesity on Diabetic Nephropathy in Chinese Han.
|
28013303 |
2017 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
EGFR inhibition may be a therapeutic strategy in the treatment of diabetic nephropathy and in limiting salt and water retention, which currently restricts the use of PPARγ agonists.
|
23370527 |
2013 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
We examined the relationship between two PPAR-gamma gene polymorphisms, namely the P12A and C161T, and cardiovascular disease in patients with diabetic nephropathy.
|
18417957 |
2008 |
|
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist.
|
16687627 |
2006 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The genetic influence of PPARG P12A genotype is modest and is overshadowed by duration of diabetes and systolic blood pressure as the major risk factors for diabetic nephropathy in the Oji-Cree population.
|
17493550 |
2007 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
The genetic influence of PPARG P12A genotype is modest and is overshadowed by duration of diabetes and systolic blood pressure as the major risk factors for diabetic nephropathy in the Oji-Cree population.
|
17493550 |
2007 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of the present study is to identify the regulation of lncRNA TUG1 on extracellular matrix accumulation via mediating microRNA-377 targeting of PPARγ, and investigate the underlying mechanisms in progression of DN.
|
28137588 |
2017 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Herein, we asked whether miR-27a mediates podocyte injury through PPARγ/β-catenin signaling in DN.
|
28277542 |
2017 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We conclude that P12A and C161T polymorphisms of the PPAR-gamma gene are important predictors of cardiovascular event in patients with diabetic nephropathy.
|
18417957 |
2008 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes.
|
14633865 |
2003 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The +A2962G of PPARGC1A and the 3 polymorphisms of PPARG were not associated with DN.
|
19900151 |
2010 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the role of PPAR-gamma in proximal tubular cells with respect to cell growth and inflammation in diabetic nephropathy is largely unknown.
|
15113752 |
2004 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
For this purpose, we performed a microarray analysis on kidneys of 3-wk-old peroxisome proliferator-activated receptor-γ (PPARγ)-null and AZIP/F1 mice, which are two models of diabetic nephropathy due to lipodystrophy.
|
29488390 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Quantitative results of reverse transcriptase polymerase chain reaction demonstrated that compared with the placebo, CQ10 administration upregulated gene expression of peroxisome proliferator-activated receptor-γ (P = .02) in peripheral blood mononuclear cells of the patients with DN.
|
29421772 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator activated receptor-gamma (PPAR-γ) is implicated in several metabolic syndromes including Diabetic Nephropathy, besides obesity, insulin insensitivity, dislipidemia, inflammation, and hypertension.
|
28539091 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We and others have shown that SIRT1 exerts renoprotective effects in DKD in part through the deacetylation of transcription factors involved in the disease pathogenesis, such as p53, FOXO, RelA/p65NF-κB, STAT3, and PGC1α/PPARγ.
|
30386303 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that the Pro12Ala polymorphism of the PPARG gene may be associated with diabetic nephropathy among Asians.
|
22103651 |
2012 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We aim to investigate Turkish type 2 diabetic patients with/without diabetic nephropathy and healthy group and examined the contribution of the G/C exon 2 and T/C exon 6 of the PPAR gamma gene polymorphism to the development of diabetic nephropathy.
|
17681394 |
2007 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Evidence shows that PPAR-gamma agonists also ameliorate renal fibrotic lesions in both diabetic nephropathy and nondiabetic chronic kidney disease.
|
16291834 |
2006 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes.
|
19506043 |
2009 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma 2 gene is suggested to associate with diabetic nephropathy and cardiovascular disease in type 2 diabetes.
|
18467141 |
2008 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
CTD_human |
Nephropathy in Pparg-null mice highlights PPARγ systemic activities in metabolism and in the immune system.
|
28182703 |
2017 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, in line with the role of PPARγ in metabolic homeostasis, Pparg null-mice first represent a potent model for studying the initiation and the development of diabetic nephropathy.
|
28182703 |
2017 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Trigonelline reduced diabetic nephropathy and insulin resistance in type 2 diabetic rats through peroxisome proliferator-activated receptor-γ.
|
31363374 |
2019 |